Key Points
- David Bredt sold 8,500 RAPP shares on Jan. 15 at an average price of $26.84 for $228,140, leaving him with 395,575 shares (a 2.10% reduction in his position).
- The Jan. 15 sale continues a recent pattern of insider disposals — Bredt also sold 8,500 shares on Nov. 17 ($25.19), 8,500 on Dec. 15 ($30.02) and 6,567 on Dec. 31 ($30.05).
- Rapport Therapeutics is a clinical-stage oncology biotech with a $1.28B market cap and an analyst consensus of "Moderate Buy" with an average price target of $48.33.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $26.84, for a total transaction of $228,140.00. Following the sale, the insider directly owned 395,575 shares of the company's stock, valued at $10,617,233. This represents a 2.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
David Bredt also recently made the following trade(s):
- On Wednesday, December 31st, David Bredt sold 6,567 shares of Rapport Therapeutics stock. The stock was sold at an average price of $30.05, for a total transaction of $197,338.35.
- On Monday, December 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.02, for a total transaction of $255,170.00.
- On Monday, November 17th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.19, for a total transaction of $214,115.00.
Rapport Therapeutics Stock Down 0.2%
RAPP stock opened at $26.81 on Friday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -9.89 and a beta of 1.63. Rapport Therapeutics, Inc. has a 12-month low of $6.43 and a 12-month high of $42.27. The company's fifty day simple moving average is $28.40 and its 200 day simple moving average is $23.18.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.06. Research analysts expect that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.
Analyst Ratings Changes
RAPP has been the topic of a number of research analyst reports. Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a report on Thursday, January 8th. HC Wainwright boosted their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, December 9th. Citizens Jmp raised their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the stock a "market outperform" rating in a report on Friday, November 7th. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Rapport Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $48.33.
View Our Latest Research Report on RAPP
Institutional Investors Weigh In On Rapport Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in Rapport Therapeutics during the 3rd quarter valued at about $43,000. Strs Ohio raised its stake in shares of Rapport Therapeutics by 23.5% in the third quarter. Strs Ohio now owns 2,100 shares of the company's stock worth $62,000 after purchasing an additional 400 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after purchasing an additional 4,582 shares in the last quarter. Creative Planning purchased a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $121,000. Finally, Kennedy Capital Management LLC bought a new stake in Rapport Therapeutics during the second quarter worth $128,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
